Synonym
PF-05175157; PF05175157; PF 05175157.
IUPAC/Chemical Name
1,4-Dihydro-1'-[(2-methyl-1H-benzimidazol-6-yl)carbonyl]-1-(1-methylethyl)-spiro[5H-indazole-5,4'-piperidin]-7(6H)-one
InChi Key
BDXXSFOJPYSYOC-UHFFFAOYSA-N
InChi Code
InChI=1S/C23H27N5O2/c1-14(2)28-21-17(13-24-28)11-23(12-20(21)29)6-8-27(9-7-23)22(30)16-4-5-18-19(10-16)26-15(3)25-18/h4-5,10,13-14H,6-9,11-12H2,1-3H3,(H,25,26)
SMILES Code
O=C1CC2(CCN(C(C3=CC=C4N=C(C)NC4=C3)=O)CC2)CC5=C1N(C(C)C)N=C5
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Biological target:
PF-05175157 is broad spectrum acetyl-CoA carboxylase (ACC) inhibitor with IC50s of 27.0, 33.0, 23.5 and 50.4 nM for ACC1 (human), ACC2 (human), ACC1 (rat), ACC2 (rat), respectively.
In vitro activity:
PF-05175157 is broad spectrum acetyl-CoA carboxylase (ACC) inhibitor with IC50s of 27.0±2.7, 33.0±4.1, 23.5±1.1 and 50.4±2.6 nM for ACC1 (human), ACC2 (human), ACC1 (rat) and ACC2 (rat), respectively. The in vitro metabolism of PF-05175157 (Compound 9) is evaluated in microsomes from rat, dog, and human hepatocytes. PF-05175157 is not metabolized in rat, dog, or human microsomes. PF-05175157 is also stable in human hepatocyte incubations, but is minimally metabolized by recombinant human CYP3A4 and CYP3A5. PF-05175157 inhibits formation of malonyl-CoA in a concentration-dependent manner with a potency (EC50=30 nM) in rat hepatocytes consistent with its potency against rat ACC1 (24 nM).
Reference: J Med Chem. 2014 Dec 26;57(24):10512-26. https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/25423286/
In vivo activity:
Oral administration (3 mg/kg) to rats and dogs show bioavailability of 40% and 54%, respectively, consistent with the low microsomal clearance and good solubility at low pH. Formation of the direct product of ACC, malonyl-CoA, in the skeletal muscle and liver of lean rats is assessed 1 h following an acute oral dose of PF-05175157, showing concentration-dependent reductions in both skeletal muscle and liver malonyl-CoA. At the nadir, quadriceps and liver malonyl-CoA levels are reduced by 76% and 89%, respectively. The EC50s for inhibition of quadriceps and liver malonyl-CoA are 870 and 540 nM, respectively, determined from unbind plasma concentrations of PF-05175157. Acute oral administration of PF-05175157 inhibits hepatic DNL in rats in an unbind plasma drug concentration-dependent manner. PF-05175157 inhibits up to 82% of the incorporation of [14C]acetate into [14C]lipids with an EC50 of 326 nM.
Reference: J Med Chem. 2014 Dec 26;57(24):10512-26. https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/25423286/
|
Solvent |
mg/mL |
mM |
comments |
| Solubility |
| DMSO |
20.0 |
49.38 |
|
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
405.50
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
Formulation protocol:
David A, et al. Decreasing the Rate of Metabolic Ketone Reduction in the Discovery of a Clinical Acetyl-CoA Carboxylase Inhibitor for the Treatment of Diabetes. J Med Chem. 2014 Dec 26; 57(24): 10512–10526.
In vitro protocol:
David A, et al. Decreasing the Rate of Metabolic Ketone Reduction in the Discovery of a Clinical Acetyl-CoA Carboxylase Inhibitor for the Treatment of Diabetes. J Med Chem. 2014 Dec 26; 57(24): 10512–10526.
In vivo protocol:
Catlin NR, Bowman CJ, Campion SN, Davenport SD, Esler WP, Kumpf SW, Lewis EM, Nowland WS, Ross TT, Stedman DS, Stethem C, Cappon GD. Inhibition of ACC causes malformations in rats and rabbits: comparison of mammalian findings and alternative assays. Toxicol Sci. 2020 Nov 28:kfaa169. doi: 10.1093/toxsci/kfaa169. Epub ahead of print. PMID: 33247737.
1: Karsch L. Derivation of a formula describing the saturation correction of plane-parallel ionization chambers in pulsed fields with arbitrary repetition rate. Phys Med Biol. 2016 Mar 30;61(8):3222-3236. [Epub ahead of print] PubMed PMID: 27028952.
2: Pongcharoen B, Reutiwarangkoon C. The comparison of anterior knee pain in severe and non severe arthritis of the lateral facet of the patella following a mobile bearing unicompartmental knee arthroplasty. Springerplus. 2016 Feb 27;5:202. doi: 10.1186/s40064-016-1914-1. eCollection 2016. PubMed PMID: 27026898.
3: Churilla JR, Richardson MR, Pinkstaff SO, Fletcher BJ, Fletcher GF. Associations between heart failure and physical function in U.S. adults. QJM. 2016 Mar 29. pii: hcw042. [Epub ahead of print] PubMed PMID: 27026699.
4: Galić I, Mihanović F, Giuliodori A, Conforti F, Cingolani M, Cameriere R. Accuracy of scoring of the epiphyses at the knee joint (SKJ) for assessing legal adult age of 18 years. Int J Legal Med. 2016 Mar 30. [Epub ahead of print] PubMed PMID: 27025716.
5: Shimizu T, Fukuoka K, Takeda M, Iwasa T, Yoshida T, Horobin J, Keegan M, Vaickus L, Chavan A, Padval M, Nakagawa K. A first-in-Asian phase 1 study to evaluate safety, pharmacokinetics and clinical activity of VS-6063, a focal adhesion kinase (FAK) inhibitor in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol. 2016 Mar 30. [Epub ahead of print] PubMed PMID: 27025608.
6: Smolyakov G, Formosa-Dague C, Severac C, Duval RE, Dague E. High speed indentation measures by FV, QI and QNM introduce a new understanding of bionanomechanical experiments. Micron. 2016 Mar 11;85:8-14. doi: 10.1016/j.micron.2016.03.002. [Epub ahead of print] PubMed PMID: 27023832.
7: Bayhan Z, Zeren S, Kocak FE, Kocak C, Akcılar R, Kargı E, Tiryaki C, Yaylak F, Akcılar A. Antiadhesive and anti-inflammatory effects of pirfenidone in postoperative intra-abdominal adhesion in an experimental rat model. J Surg Res. 2016 Apr;201(2):348-55. doi: 10.1016/j.jss.2015.11.033. Epub 2015 Nov 25. PubMed PMID: 27020818.
8: Bragança CA, Damm U, Baroncelli R, Massola Júnior NS, Crous PW. Species of the Colletotrichum acutatum complex associated with anthracnose diseases of fruit in Brazil. Fungal Biol. 2016 Apr;120(4):547-61. doi: 10.1016/j.funbio.2016.01.011. Epub 2016 Feb 2. PubMed PMID: 27020156.
9: Shanmugam K, Subburathinam K, Velayuthampalayam Palanisamy A. A Dynamic Probabilistic Based Broadcasting Scheme for MANETs. ScientificWorldJournal. 2016;2016:1832026. doi: 10.1155/2016/1832026. Epub 2016 Feb 25. PubMed PMID: 27019868.
10: Sikora J, Mielczarek-Palacz A, Kondera-Anasz Z. Association of the Precursor of Interleukin-1β and Peritoneal Inflammation-Role in Pathogenesis of Endometriosis. J Clin Lab Anal. 2016 Mar 28. doi: 10.1002/jcla.21944. [Epub ahead of print] PubMed PMID: 27018977.
